Reuters: Novartis says Glivec misses main goal in study

[NaDiNe]

Novartis says Glivec misses main goal in study
      

ZURICH (Reuters) - Novartis AG's cancer drug Glivec failed to meet its main target in a late-stage study of patients with chronic myeloid leukaemia (CML), the Swiss drugmaker said on Friday.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login